Key Takeaways
- Record year, Q4 margin pinch: FY26 was the best year in company history on revenue, profitability and cash flow, but Q4 EBITDA margin compressed to 15.5% as metal prices rose and the company invested ahead in manpower for expected strong FY27 growth.
- Transformation into a solutions company is now operational: The evolution from glass-lined equipment maker to integrated precision engineering and turnkey solutions provider is complete, with acquisitions fully integrated and new product lines like shell-and-tube glass-lined heat exchangers reaching commercial validation.
- Export engine doubled and is expected to double again: FY26 export revenue doubled over FY25, and management expects another doubling in FY27, though acceptance of Indian products remains a challenge.
- A 36-acre greenfield campus unlocks heavy-industry adjacencies: Construction has started on a new advanced manufacturing campus targeting oil and gas, nuclear engineering, food and beverages, and heavy precision engineering, with the first phase operational by April 2027.
- What to watch next quarter: Whether the pending USD0.35 crore export order clears, the formal launch of conductivity glass-lining reactors with global partner IPP, and any quantification of the margin recovery path beyond "better than FY26."
The Solutions Pivot and Product Evolution
- One-stop-shop positioning: The company has added engineering and execution capability to its equipment manufacturing base, a combination management describes as unique globally and the foundation for selling solutions rather than standalone equipment.
- Margin uplift thesis: Management believes selling solutions inherently commands better margins than selling products, because product-only sales face constant competitive comparisons while solutions pricing reflects the integrated value delivered.
- Shell-and-tube glass-lined heat exchangers: Developed with Japanese partner GL HAKKO, over 200 units are in the order book and 100 have been delivered, marking commercial validation at scale. Partial manufacturing in India started in April, with full-fledged production beginning July 1.
- Conductivity glass-lining reactors: Multiple units manufactured, supplied and validated in the field with encouraging feedback from the regulated pharma market; international partner IPP has expressed strong interest in global distribution, and a formal launch is promised in the quarter ahead.
- Pre-cast production blocks: A new subsidiary has been floated for pre-cast buildings, strictly for pharma and chemical production blocks, not domestic buildings; the capability allows construction of production blocks within six months.
Ikeda: "we have started evolution from equipment manufacturing company. Now we are adding engineering capability, execution capability, so we are becoming a One-Stop Solution Company, which is very unique and I have never seen such a company globally."
Margin Dynamics and the Investment Cycle
- Q4 gross margin drop: Gross margins fell from approximately 39% in Q3 to 32% in Q4, driven by commodity price increases in key input raw materials and deliberate investment in manpower recruited for expected stronger growth in FY27.
- The recovery logic rests on operating leverage: Management's primary margin-recovery lever is revenue volume growth itself, supplemented by tighter procurement discipline and ongoing efficiency improvements across manufacturing and project execution.
- Manpower cost is a pre-investment: The company recruited many higher-end employees for future growth, and management states this cost will be covered in coming years as revenue grows.
- FY27 margin commitment is directional, not quantified: Management repeatedly declined to give a specific EBITDA margin figure for FY27, stating only "margins going to improve, definitely" and "better than FY26," and would not confirm an analyst's 16-17% suggestion.
- Inventory build is intentional: Inventory doubled because of exports and projects requiring integration; the company procures metals immediately upon receiving an order to mitigate price volatility, and is building stock to reduce lead and delivery times for an expected very high-growth year.
Kandula: "We are product-based always comparisons, always competition, but whenever we are going to provide to customer solutions, our margins are going to improve, that is believed."
Export Trajectory and International Reach
- Export revenue doubled in FY26 and management expects it to double again in FY27, driven by inquiry conversion and supply execution.
- Geographic spread is balanced: Opportunities are coming equally from Europe, the US and the Middle East, with no single region dominating the pipeline.
- Acceptance friction persists: The challenge remains in acceptance of Indian-manufactured products in global markets, a structural headwind the company is working through as it scales.
- Pending order spillover: A USD0.35 crore export equipment order was almost ready but the client asked to wait; management expects it to clear in Q1 FY27 at the latest.
- Global leadership appointment: Mr. Yasuyuki Ikeda has been re-designated from Non-Executive to Executive Director to lead global operations and marketing, with a mandate to double down on technology partnerships and expand international reach.
Ikeda: "having this Japanese strength, the quality contrast, conservative, keep the promise, with the Indian good culture, this combination is very -- not only the Indian customers can benefit from our collaboration, but we would like to tackle global market in the future."
Greenfield Campus and Capacity Expansion
- 36-acre integrated advanced manufacturing campus: Construction is progressing on plan and will open the door to oil and gas, nuclear engineering, food and beverages, and heavy precision engineering, sectors the company does not currently serve at scale.
- Phased timeline: The first phase will be operational by April 1, 2027, with 50% of capacity coming into operations at that point; the second phase is targeted for April 1, 2028.
- Nuclear sector entry: The company expects to enter the nuclear sector by FY28, enabled by the new campus.
- Existing facility modernization: Current facilities are being upgraded with robotic and automatic welding machines and automatic polishing machines, adding approximately 30% capacity with another INR35-40 crores of investment.
- Active global partnership discussions are underway in several new areas tied to the campus expansion, though no specifics were disclosed.
Acquisitions, Integration and Capital Allocation
- Two acquisitions completed and integrated: Scigenics (bioprocess and fermentation systems) and Standard C2C Engineering (process, civil, HVAC, electrical and instrumentation engineering) were acquired and fully integrated during FY26, bringing critical engineering capabilities in-house.
- FY27 targets for acquired entities: Both C2C Engineering and Scigenics are each targeted to contribute INR60 crores in revenue in FY27.
- Working capital tightened while expanding: The working capital cycle improved from 174 days to 150 days, and operating cash flow swung from INR5 crores to INR45 crores.
- Future acquisitions are part of the strategy: Management stated the company will acquire more companies as part of a sustainable growth strategy combining organic and inorganic growth, but emphasized that acquisitions must be strategic, not merely additive to revenue.
- Free cash flow ambition: Management confirmed a target of good-quality free cash flow generation in the next two years.
Ikeda: "Just acquiring a company is just adding number, and this is not what we should focus. So, the organic growth, the combination of organic growth and the inorganic growth is necessary for our sustainable growth."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | FY27 revenue growth better than FY26; quarterly run rate of INR250-300 crores "definitely" achievable | FY27 |
| EBITDA margin | Margins will improve, better than FY26 (no figure confirmed) | FY27 |
| Export growth | Export revenue to double again over FY26 | FY27 |
| Pending export order | USD0.35 crore equipment order to clear | Q1 FY27 max |
| C2C Engineering revenue | Target INR60 crores | FY27 |
| Scigenics revenue | Target INR60 crores | FY27 |
| Heat exchanger full production | Full-fledged manufacturing starts | July 1, 2027 |
| Greenfield campus Phase 1 | First phase operational, 50% capacity online | April 1, 2027 |
| Greenfield campus Phase 2 | Second phase operational | April 1, 2028 |
| Nuclear sector entry | Company expects to enter nuclear sector | FY28 |
| Conductivity glass-lining reactors | Formal launch with IPP global distribution | Quarter ahead |
| Free cash flow | Good-quality free cash flow generation | Next two years |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Total income | ₹231 cr, 35% growth |
| EBITDA | ₹36 cr, 26% growth, 15.5% margin |
| Profit before tax | ₹29 cr, 28.4% growth |
| Profit after tax | ₹21 cr, 27.8% growth, PAT margin 9.1% |
| Gross margin | 32%, declined from ~39% in Q3 |
| Total income (FY26) | ₹793 cr, 26.7% YoY growth |
| EBITDA (FY26) | ₹138 cr, 15.2% YoY growth, EBITDA margin 17.4% |
| PAT (FY26) | ₹83 cr, 21% YoY growth, PAT margin 10.5% |
| EPS (FY26) | ₹4, improved |
| Operating cash flow (FY26) | ₹45 cr, positive, improved from ₹5 cr in FY25 |
| Working capital days (FY26) | 150 days, improved from 174 days in FY25 |
| Order book | ~₹1,000 cr, execution timeline 8–10 months |
| Export share of order book | ₹30 cr, balance domestic |
| Export revenue growth (FY26) | Doubled compared to FY25 |
| Export as % of Q4 revenue | 5.3%, against earlier guidance of 12–13% [11–12] |
| Capex (FY26) | ₹40 cr |
| Planned capex (next 2 years) | ₹130 cr on greenfield facility, ₹65 cr each year |
| Existing plant utilization | 70–80% |
| C2C Engineering revenue (FY26) | ₹24 cr, FY27 target ₹60 cr |
| Scigenics revenue (FY26) | ~₹20 cr, FY27 target ₹60 cr |
| Glass-lined heat exchangers delivered | 100 units delivered, over 200 in order book |
| Inventory | ₹438 cr, aging less than 180 days, no dead inventory |